Janux Therapeutics Inc (JANX)
NASDAQ:JANX
JANX Stock Chart & Stats
$13.63
-$2.71(-4.69%)
At close: 4:00 PM EST
$13.63
-$2.71(-4.69%)
Day’s Range― - ―
52-Week Range$12.12 - $35.34
Previous CloseN/A
Volume1.13M
Average Volume (3M)1.02M
Market Cap
$829.14M
Enterprise Value$818.69M
Total Cash (Recent Filing)$966.57M
Total Debt (Recent Filing)$41.88M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 12, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding60,831,657
10 Day Avg. Volume1,352,589
30 Day Avg. Volume1,022,845
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.89
Price to Sales (P/S)85.51
P/FCF Ratio-10.27
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue45.79
Enterprise Value/Gross Profit97.01
Enterprise Value/Ebitda-6.10
Forecast
1Y Price Target
$54.00Price Target Upside296.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.61
Revenue Forecast (FY)$10.14M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And TolerabilityAnalyst highlights interim JANX007 data showing competitive tumor responses and favorable prostate-specific antigen reductions alongside a mitigation protocol that reduced severe cytokine release, supporting potential outpatient dosing and broader clinical use.
Platform Diversification Into AutoimmuneAnalyst emphasizes initiation of healthy volunteer testing for a CD19-targeted bispecific built on the ARM platform, which could differentiate the company by offering off-the-shelf autoimmune therapy with less frequent dosing and lower infection and cytokine risks.
Strategic PartnershipAnalyst views the exclusive collaboration and license with a major pharmaceutical company as external validation that monetizes the tumor-activated platform while allowing capital and focus to remain on internally owned clinical assets.
Bears Say
Competitive And Market PressureAnalyst points out strong early results from a competitor's prostate cancer T-cell engager and a dramatic share price decline after the interim update, increasing commercial and investor-confidence pressure on the company's programs.
Data Robustness And Dosing UncertaintyAnalyst notes that small patient cohorts, declines in RECIST response rates, and lack of confirmed response disclosure create uncertainty about durability of benefit and complicate selection of a definitive dose and schedule for pivotal trials.
Safety ConcernsAnalyst warns that a fatal cardiotoxicity event tied to the program raises material safety concerns that will prompt heightened monitoring and could constrain regulatory and commercial prospects.
Janux Therapeutics Inc News
JANX FAQ
What was Janux Therapeutics Inc’s price range in the past 12 months?
Janux Therapeutics Inc lowest stock price was $12.12 and its highest was $35.34 in the past 12 months.
What is Janux Therapeutics Inc’s market cap?
Janux Therapeutics Inc’s market cap is $829.14M.
When is Janux Therapeutics Inc’s upcoming earnings report date?
Janux Therapeutics Inc’s upcoming earnings report date is May 12, 2026 which is in 45 days.
How were Janux Therapeutics Inc’s earnings last quarter?
Janux Therapeutics Inc released its earnings results on Feb 26, 2026. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.625 by $0.115.
Is Janux Therapeutics Inc overvalued?
According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued.
Does Janux Therapeutics Inc pay dividends?
Janux Therapeutics Inc does not currently pay dividends.
What is Janux Therapeutics Inc’s EPS estimate?
Janux Therapeutics Inc’s EPS estimate is -0.59.
How many shares outstanding does Janux Therapeutics Inc have?
Janux Therapeutics Inc has 60,831,657 shares outstanding.
What happened to Janux Therapeutics Inc’s price movement after its last earnings report?
Janux Therapeutics Inc reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.625. Following the earnings report the stock price went down -1.377%.
Which hedge fund is a major shareholder of Janux Therapeutics Inc?
Currently, no hedge funds are holding shares in JANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Janux Therapeutics Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.00 (296.18% Upside)
$54.00 (296.18% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 332.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $173.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.23%
12-Months-Change
Fundamentals
Return on Equity
-11.55%
Trailing 12-Months
Asset Growth
-5.09%
Trailing 12-Months
Company Description
Janux Therapeutics Inc
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX Stock 12 Month Forecast
Average Price Target
$54.00
▲(296.18% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Vera Therapeutics
―
Biohaven Ltd.
―
Ownership Overview
Currently, No data available
---